Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress ...

When the drug binds to CD47, it helps destroy the cancer cells directly. In the study, magrolimab was combined with docetaxel, a type of chemotherapy. The study included 31 patients with metastatic ...

Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk ...

These findings show promise to improve the efficacy of docetaxel-based chemotherapy in patients with prostate cancer. Co-lead investigator Maximilian P. Brandt, MD, Department of Urology and Pediatric ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

While stage 4 breast cancer is challenging, there are several effective treatment options available that can help manage the disease and improve quality of life.

Module 2 included 4 patients with non-small cell lung cancer (NSCLC) or pleural mesothelioma who had disease progression on, or were unable to tolerate, prior chemotherapy-containing regimens.

Increasing evidence suggests that chemotherapy in hormone-refractory prostate cancer improves both quality of life and survival. Tannock et al. [8] examined docetaxel plus prednisone and ...

Get detailed information on Docetaxel, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy.

Kate Middleton is in her comeback era. The Princess of Wales, 42, is working out again after completing chemotherapy in September, according to royal expert Robert Jobson. “From what I ...

Darolutamide plus androgen deprivation therapy (ADT), without docetaxel, significantly prolonged radiographic progression-free survival compared with placebo plus ADT in patients with metastatic ...